Fusion Pharmaceuticals

General Information
Business:

 

We are a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. We have developed our Targeted Alpha Therapies, or TAT, platform together with our proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Our TAT platform is underpinned by our research and insights into the underlying biology of alpha emitting radiopharmaceuticals as well as our differentiated capabilities in target identification, candidate generation, manufacturing and supply chain and development of imaging diagnostics. 

Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)
Employees: 40
Founded: 2014
Contact Information
Address 270 Longwood Road South, Hamilton, ON, L8P 0A6
Phone Number (289) 799-0891
Web Address http://www.fusionpharma.com
View Prospectus: Fusion Pharmaceuticals
Financial Information
Market Cap $708.3mil
Revenues $0 mil (last 12 months)
Net Income $-23.9 mil (last 12 months)
IPO Profile
Symbol FUSN
Exchange NASDAQ
Shares (millions): 12.5
Price range $17.00 - $17.00
Est. $ Volume $212.5 mil
Manager / Joint Managers Morgan Stanley/ Jefferies/ Cowen
CO-Managers Wedbush PacGrow
Expected To Trade: 6/26/2020
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change